CYTO

[stocks2watch2]

Bought 5000 @ 3.12. Recent news,

Positive Findings from Clinical Studies of QUADRAMET(R) in Prostate Cancer Patients with Metastatic Bone Disease Presented at ASCO Prostate Cancer Symposium
PR Newswire (Mon 6:00am) 

http://biz.yahoo.com/prnews/060227/nym076.html?.v=31

Cytogen Reports Fourth Quarter and Full Year 2005 Financial Results
PR Newswire (Thu, Feb 23) 

http://biz.yahoo.com/prnews/060223/phth006.html?.v=44

[stocks2watch2]

Sold 1/2 @ 3.42

[Terliso]

Looking great!! CYTO made a breakaway Gap 

[dwest718]

CYTO is looking technically sound again.  I'll post my chart and analysis on Sunday night when I have access to the usual resources.  Still holding the shares I purchased around 3 ... and now thinking of at least doubling down.  Considering purchasing at least 500 shares in the middle of the week next week with some positive confirmation from the bottom that it looks like just formed.

Setravis (or whoever wants to do me a favor)  ... if you read this and you've got a bit of extra time on your hands could you post a 6 month chart with no log scale and with volume by price bars.  MACD and RSI below and circle the RSI and MACD positive divergence and then MACD cross... and then all I'll have to do is post my analysis 

[dwest718]

Funny how things can change in an hour of trading.  Looks to have formed a bearish engulfing scenario and the MACD divergence never pulled through so would need strong bullish confirmation on Monday for me to consider buying.  I'll still post chart and analysis and my trading strategy tomorrow night 

[Melf Elf]

  Looks to have formed a bearish engulfing scenario and the MACD divergence never pulled through so would need strong bullish confirmation on Monday for me to consider buying.  I'll still post chart and analysis and my trading strategy tomorrow night 

dwest,

Good obsevations.  Applause.

A few points about stocks in bear trends:

1. Bullish divergences are meaningless without price confirmation (as you basically are saying).

2. Crashes occur from oversold levels.  13-day RSI got to oversold (25) a month ago, right after the Symmetircal Triangle broke to the downside.  CYTO continued to get smashed.

3. "Cheap stocks can get a lot cheaper."

[dwest718]

CYTO is finally looking very good again 

Didn't get a chance to post on Friday but up over 25% since Thursday morning and up AH.  Sat on top of 50dma for about 2 weeks and then busted through the 200dma twice on Friday.  2-3 times average volume on Thurs. followed by 5-6 times average volume on Friday.  Looks to have busted through several midterm resistance levels as well... take a look.  I'd/I'll put a chart up if I had/have the time.

[setravis]

Here is the chart dwest718....
Making some noise....

Support @ $2.35...2.06...1.94
Resistance @ $3.15...3.38...3.51

Float (mil) 22.40

52wk Range: 1.93 - 3.95

Volume: 883,812
Avg Vol (3m): 78,210.6

Technicals
MACD is Bullish
Stochastic is Bullish
Percentage Gainer

Last Price Quote is:
24.45%above 13-day MA
29.10%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $47.69 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 11/13/2006
Last Analyst Rating: Mkt Outperform

Business Overview
BRIEF: For the six months ended 30 June 2006, Cytogen Corporation's revenues rose 6% to $8.6M. Net loss fell 97% to $460K. Revenues reflect higher QUADRAMET sales and increased PROSTASCINT income reflecting higher demand, the implementation of price increases and identification of new distribution channels. Lower loss reflects lower SG&A expenses, higher interest income and the presence of $12.9M gain on sale of equity interest in the joint venture. http://www.cytogen.com

[dwest718]

More action again today.  Sitting at day high of 3.20 right now (11:06am EST) on 250k shares (3 times average volume in first hour and a half of trading).  Has broken through first small resistance in front of it and now has a bit of room to maneuver.  We'll see where it goes but looking good so far.

[dwest718]

Continued solid price action and volume (360k over 3 hrs trading) during the beginning of the afternoon.  Ran to 3.30 early and now hovering around 3.25 ... I'll post a chart during the break between my 1 and 3 oclock class.

Thanks for the help last night setra 

[dwest718]

Nice recovery for CYTO to bounce over top of the 200dma again today.  If it can stay up, it should have some room to run in coming days.

[setravis]

"CYTO" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.    
All history on a stock pick in 1 thread is awesome.     

Thank You....and good luck with all your trades....make some $$$     


I will leave today's closing chart while I'm in this thread

[Draak]

Press Release Source: Cytogen Corporation


Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Tuesday May 22, 7:00 am ET


PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO - News) today reported outcomes data from a large cohort study demonstrating the value of PROSTASCINT® (capromab pendetide) in predicting prognosis in prostate cancer.(i) The study evaluated the outcomes of patients whose PROSTASCINT images showed uptake in the central abdomen, a finding suggestive of metastatic disease, as compared to those without such findings. In the study, prostate cancer-specific death rates were 10 times higher in patients with central abdominal uptake (CAU) than in patients without CAU (p=0.005).(i) These results further reinforce that PROSTASCINT offers a level of accuracy and detail to prostate cancer imaging that can aid clinicians in defining patients' prognoses and treatment regimens.
Source: Cytogen Corporation 


·  PROSTASCINT is the first and only commercial monoclonal antibody-based agent targeting prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. (Photo: Business Wire).  View Multimedia Gallery


       
 
PROSTASCINT is the first and only commercial monoclonal antibody-based agent that targets prostate-specific membrane antigen (PSMA) to image the extent and spread of prostate cancer. The study, "Capromab pendetide (ProstaScint) imaging with central abdominal uptake: poor outcomes for prostate cancer patients," by Haseman, et al., was presented at the 2007 Annual Meeting of the American Urological Association taking place May 19-24, 2007 in Anaheim, California.

"As the only functional imaging agent available for prostate cancer, PROSTASCINT brings greater clarity to prostate cancer imaging, enabling more precise assessment of disease," commented Michael J. Manyak, M.D., vice president of medical affairs with Cytogen. "The poor outcomes among men whose PROSTASCINT scan detected central abdominal activity support what has long been suspected -- that the detection of central abdominal activity on PROSTASCINT scans is indicative of metastatic activity. Following the presentation of eight-year outcomes data in February 2007, this outcomes study further demonstrates PROSTASCINT's utility for prognosis. The data presented here today reinforce the value of information obtained from PROSTASCINT scans to assist in selection of appropriate therapy."

The investigators reviewed records of 341 men with prostate cancer who underwent PROSTASCINT imaging between 1994 and 1999 and were followed up for a median of 4.1 years.(i) Patients were divided into two groups based on whether CAU was present or absent.(i) CAU was detected in 69 (20%) patients. Of the 262 men who received pelvic radiotherapy after the PROSCASCINT scan, 57 (83%) had evidence of CAU and 205 (75%) did not (p=0.2). Five of the 69 patients (7.2%) in the CAU group died of prostate cancer, compared to two of the 272 (0.7%) CAU-negative patients (p=0.005).(i) The ten-fold increase in prostate cancer-specific death rates was independent of the use or timing of intervention with hormone therapy. These outcomes data confirm that high signal intensity in the abdomen is a negative prognostic sign.

About Prostate Cancer

Prostate cancer is the most common type of cancer found in American men, other than skin cancer. In 2007, the American Cancer Society estimates that there will be about 219,000 new cases of prostate cancer in the United States and that about 27,000 men will die from the disease.(ii) It is estimated that more than 2 million American men are currently living with prostate cancer.(iii) Tests to determine the amount of prostate-specific antigen (PSA), a protein produced by the cells of the prostate gland, in the blood along with a digital rectal exam are used to help initially detect prostate cancer and also to monitor patients with a history of prostate cancer to see if the cancer has come back or recurred. PSA levels cannot directly identify the extent or location of disease.

About PROSTASCINT

Cytogen's PROSTASCINT molecular imaging agent is the first and only commercial product targeting prostate-specific membrane antigen or PSMA. PROSTASCINT consists of Cytogen's proprietary PSMA-targeting monoclonal antibody, 7E11-C5, linked to the imaging radioisotope Indium-111. By targeting PSMA, the PROSTASCINT molecular imaging procedure can detect the extent and spread of prostate cancer using a standard gamma camera.

Emerging data from several sources using the superimposition, or fusion, of the PROSTASCINT functional study upon an anatomic image such as Computed Tomography (CT) Imaging or Magnetic Resonance Imaging (MRI), have generated renewed interest in the clinical value of PROSTASCINT imaging. In January 2007, the National Comprehensive Cancer Network, or NCCN, updated its clinical practice guidelines and expanded PROSTASCINT's role to include recurrent disease. The expanded NCCN guidelines reflect the growing awareness of the potential for PROSTASCINT fusion imaging to assess disease and plan individualized treatment regimens.

[Draak]

May 23, 2007 - 7:02 AM EDT           


Cytogen Reports Publication Validating the Utility of its Proprietary ProChart(TM) Database
Cytogen Corporation (NASDAQ: CYTO) today reported the publication of a review validating the utility of its ProChart™ database to help define the function of the WW domain-containing oxidoreductase (WWOX), an important tumor suppressor gene with known involvement in breast, prostate, lung, pancreatic, esophageal, and gastric cancers. The peer-reviewed article was published in the online edition (25 April 2007) of the Journal of Cellular Physiology as a Mini Review entitled "WWOX in biological control and tumorigenesis," by Rami I. Aqeilan and Carlo M. Croce, epub 25 April 2007. The publication focuses on the most recent progress in understanding the function of WWOX as a tumor suppressor.

WW and other modular domain families are known to be important in mediating many important protein-protein interactions. Because WWOX contains two WW domains, it was an ideal protein to analyze with ProChart, Cytogen's proprietary, comprehensive, experimentally validated database of protein-protein signaling interactions. Using ProChart, the authors were able to determine a number of novel WWOX-interacting proteins, including the transcription factors p73 and Ap-2 gamma, the latter of which is known to play a role in activating the expression of the epidermal growth factor, HER2 (erbB-2). The study also reviews the importance of the relationships between WWOX and critical proto-oncogenes such as ErbB4 and c-Jun.

Using ProChart to accelerate their studies of WWOX, in recent years researchers from Ohio State University have validated a number of key WWOX interactions and published several peer-reviewed journal articles. Prior to the application of ProChart, little was known about the specific biologic functions of WWOX protein expression or the signaling pathways that lead to its tumor suppressive effects. In the current publication, the authors specifically refer to the usefulness of the ProChart data to help them define the WWOX pathway and its role in tumor suppression.

While Cytogen's internal research and development initiatives focus on clinical-stage opportunities, the Company complements its internal programs with an active business development strategy, which includes capitalizing on the promising proprietary technology platforms, such as ProChart, previously developed through its AxCell BioSciences research-stage subsidiary.

In view of recent biological validation, as well as the progress of internal data mining efforts and external research collaborations, Cytogen is exploring strategic transactions for AxCell BioSciences and will be presenting today at the 9th Annual C21 BioVentures Conference (C21) taking place in Monterey, California.

About ProChart™

ProChart is a proprietary, comprehensive, experimentally validated database of protein-protein signaling interactions mediated by WW, SH3, PDZ, and other modular domain families. Cytogen believes the application of ProChart may accelerate research and drug development by: (i) discovering novel signal transduction pathways and their relevant protein-protein interactions; (ii) rapidly identifying qualified drug targets; (iii) identifying potential unwanted side effects; (iv) identifying structure and activity relationship (SAR) information regarding domain and ligand interactions that can facilitate small molecule drug design; and (v) providing high throughput screening reagents (eg, cloned domains and ligands).

About Cytogen

Cytogen is a specialty pharmaceutical company dedicated to advancing the treatment and care of patients by building, developing, and commercializing a portfolio of oncology products. The Company's specialized sales force currently markets three therapeutic products and one diagnostic product to the U.S. oncology market. CAPHOSOL® is an advanced electrolyte solution for the treatment of oral mucositis and dry mouth that is approved in the U.S. as a prescription medical device. QUADRAMET® (samarium Sm-153 lexidronam injection) is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT® (capromab pendetide) is a PSMA-targeting monoclonal antibody-based agent to image the extent and spread of prostate cancer and SOLTAMOX™ (tamoxifen citrate) is the first liquid hormonal therapy approved in the U.S. for the treatment of breast cancer in adjuvant and metastatic settings. The Company is also developing CYT-500, a third-generation radiolabeled antibody to treat prostate cancer. Cytogen's product-focused strategy centers on attaining sustainable growth through clinical, commercial, and strategic initiatives.